Posted by Michael Wonder on 07 Jan 2022
Keytruda (pembrolizumab) plus Lenvima (lenvatinib) approved in Japan for patients with unresectable, advanced or recurrent endometrial carcinoma that progressed after cancer chemotherapy
27 December 2021 - First approval in Japan for the Keytruda plus Lenvima combination.
Merck and Eisai today announced that the Japanese MHLW has approved the combination of Keytruda plus Lenvima for the treatment of patients with unresectable, advanced or recurrent endometrial carcinoma that progressed after cancer chemotherapy.
